Update information
June 2018: Recommendations 1.1 and 1.2 were amended to clarify that they refer to monotherapy. Recommendation 1.3 was updated and replaced by recommendation 1.5.5 in the NICE guideline on dementia.
May 2016: Recommendation 1.3 in this technology appraisal was partially updated by recommendation 1.6.2.3 in NICE's previous guideline on dementia (NICE guideline CG42). Specifically:
-
non-specialists can now prescribe donezepil, galantamine, rivastigmine and memantine, as long as they have taken advice from a clinician who has the necessary knowledge and skills. This includes:
-
secondary care medical specialists such as psychiatrists, geriatricians and neurologists
-
other healthcare professionals such as GPs, nurse consultants and advanced nurse practitioners with specialist expertise in diagnosing and treating Alzheimer's disease
-
-
local arrangements for prescribing, supply, and treatment review should follow the NICE guideline on medicines optimisation.
February 2014: Implementation section was updated to clarify that donepezil, galantamine, rivastigmine and memantine are recommended as options for treating Alzheimer's disease.
ISBN: 978-1-4731-1898-0